Referrals to phase I clinical trials in a gynecologic oncology unit.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2013.09.003PMID 24041878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2013

  2013cited by this paper
• A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2012cited by this paper
• A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

  2012cited by this paper
• A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  2012cited by this paper
• A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

  2011cited by this paper
• Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2011cited by this paper
• Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

  2011cited by this paper
• Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment

  2010cited by this paper
• Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

  2010cited by this paper
• Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Management of recurrent ovarian carcinoma: current status and future directions.

  2009cited by this paper
• Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.

  2009cited by this paper
• Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.

  2009cited by this paper
• Management of advanced-stage and recurrent endometrial cancer.

  2009cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cited by this paper
• Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

  2006cited by this paper
• Rethinking risk-benefit assessment for phase I cancer trials.

  2006cited by this paper
• Risks and benefits of phase 1 oncology trials, 1991 through 2002.

  2005cited by this paper
• Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

  2005cited by this paper
• Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

  2004cited by this paper
• Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan

  2004cited by this paper
• Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Resistant Ovarian Cancer: A Gynecologic Oncology Group Study

  2002cited by this paper
• Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study.

  2001cited by this paper
• Phase I clinical trial design in cancer drug development.

  2000cited by this paper
• Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

  2000cited by this paper
• Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.

  1998cited by this paper
• A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

  1996cited by this paper
• Therapeutic response in phase I trials of antineoplastic agents.

  1986cited by this paper

• Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity.

  2020cites this paper